Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PharmaCyte Biotech, Inc.
Report date December 28, 2022 · Filed December 30, 2022
Section 16 reporting ended · disclosed 2022-12-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2032-11-14 | Direct | 125,000 |
Reported balance
After 2022-12-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-28 · Grant · Acquired 125,000 · Balance 125,000 F1: The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2022 Filed Dec 30, 2022 21:05 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001683168-22-008707 · ownership.xml · derivative · entry 1 Farb Daniel Stuart · CIK 0001776353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-11-14 F1 · date: The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022. F1 · derivative.exercise_date: The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.